Fig. 5.

PSA protection against HSE requires B and T cells secreting IL-10. a Experimental design for experiments in b and c Donor WT (In black text): Naïve Rag mice were transferred with WT CD4⁺ or CD8⁺ T cells or CD19⁺ B cells 7 days before PSA treatment. Donor IL-10KO (magenta text) and WT (Blue text): four groups of naïve Rag mice were transferred with combinations of donor WT B and T cells, IL-10KO B and T cells, WT B and IL-10KO T cells, IL-10KO B and WT T cells 7-days before PSA treatment. All Rag recipients received six doses of PSA before HSV infection and ACV treatment. b Survival of B cell-depleted mice (BKO, n = 20 mice) and Rag recipients of WT single cell subsets (n = 6–9 mice/group). B cell depletion in WT mice was initiated 10 days prior to PSA treatment and continued throughout infection, ns: not significant. c Survival of Rag recipients of WT and IL-10KO combination of T and B cells (n = 10–13/group). ***p < 0.001, *p < 0.05, ns: not significant as determined by log rank (Mantel–Cox) test. FACS plots of BS CD45^high cells (left), Ly6G⁺ PMN (left middle), CD11b⁺ cells within CD45^high cells (right middle), and Ly6C^high IM and Ly6C^int CD11b⁺ PMN within CD45^high CD11b⁺ cells (right) were analyzed at day 6 pi in the BS of Rag recipients of d IL-10KO B + WT T cells (brown circle) and e WT B + IL-10KO T cells (green circle)